Unlock Strategic Intelligence with Fundz
Access exclusive insights on funding rounds, strategic shifts with FundzWatch™, Family Offices, and more — faster than your competitors.
Flindr Therapeutics B.V. announces €20 million Series A financing led by V-Bio Ventures
04/24/24, 7:09 AM
Location
ossMoney raised
€20 million
Industry
therapeutics
biotechnology
Round Type
series a
Investors
Brabantse Ontwikkelings Maatschappij (Bom), Swanbridge, Oncode Oncology Bridge Fund, Curie Capital, Flanders Future Tech Fund, Qbic Fund, Johnson & Johnson Innovation – Jjdc, Inc. (Jjdc), V Bio Ventures
Precision oncology company Flindr Therapeutics B.V. has announced a €20 million Series A financing to advance its pipeline of first-in-class, small molecule inhibitors for the treatment of cancer. The funding round was led by V-Bio Ventures, alongside other new investors Johnson & Johnson Innovation – JJDC, Inc. (JJDC), QBIC Fund, Flanders Future Tech Fund and Curie Capital, as well as existing investors Oncode Oncology Bridge Fund, Swanbridge, and Brabantse Ontwikkelings Maatschappij (BOM).
🔒 Strategic shifts and deeper insights are available for this company. Unlock full access to view hidden updates, executive moves, and more.
Company Info
Location
oss, north brabant, netherlands
Additional Info
Flindr Therapeutics, based in Oss in the Netherlands, is a private pre-clinical biotech company developing next-generation precision oncology treatments. The Company, previously called Immagene, was spun out of the Netherlands Cancer Institute (NKI) and Oncode Institute in 2020, by founders Prof Daniel Peeper, Prof Christian Blank and Dr Maarten Ligtenberg. Flindr is actively building a pipeline of highly promising, first-in-class precision oncology therapies identified through the ImmunoGram Drug Discovery Engine.
💰 Fundz Parnter Program
Earn $50–$75 per paid seat you refer to Fundz. Get your own link in 15 seconds and start earning.
No purchase necessary. Anyone can join and start earning today.
Related people
EH
MH